Hepatitis C in the Elderly: Epidemiology, Natural History, and Treatment

Mindikoğlu, Ayşe L.; Miller, Ram R.

doi:10.1016/j.cgh.2008.07.017

Cited by 27 publications

(21 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Chronic HCV infection results in the progression to liver cirrhosis and the development of hepatocellular carcinoma. The incidence of hepatocellular carcinoma in cirrhotic patients with chronic HCV infection is approximately 5% per year (2).…”

Section: Introductionmentioning

confidence: 99%

Partial Splenic Embolization Facilitates the Adherence to Peginterferon in Chronic Hepatitis C with Thrombocytopenia

et al. 2011

View full text Add to dashboard Cite

Objective Platelet counts before starting the treatment affect the discontinuation and dose reduction of peginterferon in chronic hepatitis C. Thrombocytopenia leads to failure to achieve sustained virological response. This study was undertaken to evaluate the efficacy of partial splenic embolization (PSE) prior to starting peginterferon therapy combined with ribavirin in chronic hepatitis C patients showing thrombocytopenia. Patients and MethodsWe compared the clinical features of 11 patients receiving PSE (PSE group) prior to starting the combined therapy with those of 13 patients not receiving PSE (non-PSE group). All of the patients showed platelet counts !12×10 4 /mm 3 and serum hepatitis C virus-RNA levels "100 KIU/mL at baseline. The end-point of PSE was a volume of splenic infarction over 75%. Peginterferon alpha-2b at a dose of 1.2 μg/kg was administered by subcutaneous injection once a week. The dose of ribavirin was weight adjusted. Results PSE was successfully performed without serious adverse events. The period from PSE to starting the combined therapy was 14 (6-27) days. After PSE, platelet counts were significantly increased. In PSE group, platelet counts during the combined therapy were maintained above those at baseline. In non-PSE group, platelet counts at the 2nd week after the start of the combined therapy significantly decreased to less than those at baseline. Overall, 80% adherence to expected peginterferon dose was not achieved in 5 patients (45%) of PSE group and in 11 (85%) of non-PSE group (p=0.043). Conclusion Increased platelet counts after PSE facilitates the adherence to peginterferon therapy in chronic hepatitis C patients with thrombocytopenia.

show abstract

Section: Introductionmentioning

confidence: 99%

Partial Splenic Embolization Facilitates the Adherence to Peginterferon in Chronic Hepatitis C with Thrombocytopenia

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Weliswaar is de SVR in deze populatie beter met combinatie-dan met monotherapie (met interferon -alfa). 30 Frequente nevenwerkingen( > 30 à 50 %) van interferon-alfa en ribavirine zijn respectievelijk vermoeidheid, koorts, artralgieën, hoofdpijn en respectievelijk hemolyse, dyspepsie en anemie.…”

Section: Hepatitis Bunclassified

Leverlijden bij oudere personen

Ghillemijn

Laleman

Flamaing

2011

TIJDSCHR. GERONTOLOGIE GER.

View full text Add to dashboard Cite

A non-negligible percentage of the morbidity and mortality in older persons is due to liver disease. A discussion of the clinical presentation and proposed treatment of selected liver diseases in the elderly is therefore appropriate. Based on literature we will discuss the clinical course and treatment modalities of viral and autoimmune hepatitis, hepatocellular carcinoma and drug induced liver injury in the elderly.

show abstract

“…However Sayed et al [9] reported that the highest prevalence rates in Egypt were seen in patients between 55-65 years old. The age at the time of infection was significantly associated with the development of cirrhosis [7]. The median time from the age of infection to the onset of cirrhosis that was 33 years in patients who acquired the HCV infection at the age of 21 to 30 was reported to decrease to 16 years in patients who had the infection after the age of 40 [10].…”

Section: Introductionmentioning

confidence: 99%

“…Despite the decrease in the incidence of acute hepatitis C, the prevalence of longstanding chronic hepatitis C infection is increasing among older adults [6]. Prevalence of HCV infection in elderly patients are variable allover the world, in a study that was done in Italy among 496 elderly with a mean age of 79.31 years old, the prevalence of positive HCV antibody was found to be around 11% [7]. A study from Japan revealed 8.8% and 13.1% of HCV antibody seropositivity in hospital and autopsy cases older than 60 years of age, respectively [8].…”

Section: Introductionmentioning

confidence: 99%